← back to search

Guido Reifenberger

University of Toronto · DE
Area of research
Genetics · Cancer Research
Research interest
Research interests include Glioma Diagnosis and Treatment, Epigenetics and DNA Methylation, Brain Metastases and Treatment, and Cancer Genomics and Diagnostics.
h-index
137
citations
111,398
works
1,200
NIH funding
primary concept
email

Recent publications

cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.
2026cited by 9position: contributordoi
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries.
2026cited by 0position: contributordoi
Functional synapses between neurons and small cell lung cancer
Nature 2025cited by 30position: middledoi
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
Cancer Cell 2025cited by 14position: middledoi
<scp>cIMPACT</scp> ‐ <scp>NOW</scp> update 11: Proposal on adaptation of diagnostic criteria for <scp>IDH</scp> ‐ and <scp>H3</scp> ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors
Brain Pathology 2025cited by 12position: middledoi
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant
Neuro-Oncology 2025cited by 12position: middledoi
Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma
Acta Neuropathologica 2025cited by 9position: lastdoi
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
2025cited by 8position: contributordoi
<scp>cIMPACT</scp>‐<scp>NOW</scp> update 10: Recommendations for defining new types for central nervous system tumor classification
Brain Pathology 2025cited by 7position: lastdoi
IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread
Acta Neuropathologica 2025cited by 7position: middledoi
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
medRxiv 2025cited by 5position: middledoi
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries
Neuro-Oncology 2025cited by 1position: middledoi
Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomas
Acta Neuropathologica 2025cited by 1position: middledoi
Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma
Research Square 2025cited by 1position: lastdoi
Publisher Correction: Functional synapses between neurons and small cell lung cancer
Nature 2025cited by 1position: middledoi
Data from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025cited by 0position: contributordoi
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025cited by 0position: contributordoi
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025cited by 0position: contributordoi
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025cited by 0position: contributordoi
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025cited by 0position: contributordoi
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025cited by 0position: contributordoi
Glioma
Nature Reviews Disease Primers 2024cited by 461position: lastdoi
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group
The Lancet Oncology 2024cited by 79position: middledoi
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Neuro-Oncology 2024cited by 66position: middledoi
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
2024cited by 51position: contributordoi
Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma
Acta Neuropathologica 2024cited by 45position: lastdoi
The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
2024cited by 44position: contributordoi
mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism
Nature Communications 2024cited by 44position: middledoi
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection
Neuro-Oncology 2024cited by 29position: middledoi
Direct excitatory synapses between neurons and tumor cells drive brain metastatic seeding of breast cancer and melanoma
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 16position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Weller · Center for Neurosciences74 papers (2012–2026)Andreas von Deimling · Stiftung Schleswig-Holsteinische Landesmuseen47 papers (2012–2026)Stefan M. Pfister · Université du Québec39 papers (2012–2026)Jörg Felsberg · Düsseldorf University Hospital39 papers (2012–2025)Wolfgang Wick · Heidelberger Institut für Radioonkologie35 papers (2012–2025)Manfred Westphal · Universität Hamburg27 papers (2013–2024)Marc Remke · Saarland University24 papers (2012–2023)David Capper · German Cancer Research Center23 papers (2013–2025)David Jones · Mayo Clinic in Florida23 papers (2012–2021)Daniel Picard · Universitätsklinikum des Saarlandes21 papers (2017–2023)Bettina Hentschel · Leipzig University20 papers (2013–2024)Patrick Roth · University Hospital of Zurich19 papers (2014–2024)Torsten Pietsch · German Center for Neurodegenerative Diseases18 papers (2013–2024)Michael Sabel · Düsseldorf University Hospital18 papers (2012–2021)Arndt Borkhardt · Düsseldorf University Hospital16 papers (2013–2021)Dorothee Gramatzki · University Hospital of Zurich16 papers (2013–2024)Kerstin Kaulich · Düsseldorf University Hospital16 papers (2013–2025)Gabriele Schackert · Else Kröner-Fresenius-Stiftung16 papers (2013–2021)Ulrich Herrlinger · Brain (Germany)16 papers (2014–2024)Peter Lichter · German Cancer Research Center15 papers (2012–2020)